Description
Created On: 2020-07-15
Record Count: 8
Primary Industries
- Disease
- Drugs
- Diagnostic
- Medical
- Brain Waves
- Device
- Pharmaceuticals
- Therapeutic
- Diagnostic Substances
- Delivery
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203463
U.S. Patent No. 5,269,315 Determining the Nature of Brain Lesions by Electroencephalography
U.S. Patent No. 5,309,923 Method and Apparatus for Determining Brain Activity, Including the Nature of Brain Lesions by Electroencephalography
Regents Patent Rights means The Regents interest in any of the patents listed to this Agreement and assigned to The Regents; including reissues and reexaminations all of which will be automatically incorporated in and added to and made a part of this Agreement.
Licensed Product means any article, composition, apparatus, substance, chemical, or any other material covered by Regents Patent Rights or whose manufacture, use or sale would constitute an infringement of any claim within Regents Patent Rights, or any service, article, composition, apparatus, chemical, substance, or any other material made, used, or sold by or utilizing or practicing a Licensed Method.
IPSCIO Record ID: 266352
Patent No. 8,048,646 from US Application No. 12/400,715 – NELL Peptide Expression Systems And Bone Formation Activity Of Nell Peptide
Patent No. 7,807,787 from US Application No. 12/400,714 – NELL Peptide Expression Systems And Bone Formation Activity Of Nell Peptide
Application No. 09/412,297 – NELL-1 Enhanced Bone Mineralization
Application No. 11/392,294 – NELL -1 Enhanced Bone Mineralization
Application No. 11/713,366 – NELL-1 Enhanced Bone Mineralization
Licensed Product means any article, composition, apparatus, substance, chemical, or any other material whose manufacture, use or sale would constitute an infringement of any Valid Claim within University's Patent Rights, or any service, article, composition, apparatus, chemical, substance, or any other material made, used, or sold by or utilizing or practicing a Licensed Method. This definition of Licensed Product also includes a service either used by Licensee, an Affiliate, or Sublicensee or provided by Licensee, an Affiliate or Sublicensee to its customers when such service requires the use of Licensed Product or performance of Licensed Method.
Licensed Method means any process or method whose use or practice would constitute an infringement of any Valid Claim within University's Patent Rights.
IPSCIO Record ID: 29338
The University granted to Licensee an exclusive License under The University’ interest in Provisional Patent Application No. 61/030,316 entitled Screening Test for Gestational Diabetes Mellitus filed 02/21/2008 (UCLA Case No. 2007-523-1) (University Patent Rights) in jurisdictions where Regents' Patent Rights exist, to make, have made, use, sell, offer for sale and import Licensed Products (as Licensed Products is defined in the ELA) and to practice Licensed Methods (as Licensed Methods is defined in the ELA) in all fields of use to the extent permitted by law.
Gestational diabetes (or gestational diabetes mellitus, GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during third trimester of pregnancy).
IPSCIO Record ID: 115864
The Licensed Product is any material that is either covered by Licensor’s Patent Rights or any product manufactured using the Licensed Method, in either event to the extent the manufacture, use or sale of which in a particular country infringes an unexpired valid claim of a patent or a pending claim of a patent application under Patent Rights in that country in which such patent has issued or application is pending.
The Licensed Method is any method that is covered by the claims of Licensor’s Patent Rights in the country in which such method is used, or the use or practice of which would constitute, but for the license granted to the Licensee pursuant to this Agreement, an infringement of any unexpired, valid issued claim or pending claim under Patent Rights in that country in which the Licensed Method is used or practiced.
(a) U.S. Patent Application serial no. 150,159, filed 29 Jan 88,(abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;
(b) U.S. Patent Application serial no. 299,397, filed 24 Jan 89, as a continuation-in-part application of (a), (abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;
(c) U.S. Patent Application serial no. 771,483, filed 04 Oct 91, as a continuation-in-part of (b) (now allowed) by Dr. Richard Guy, et al., and assigned to The Regents;
(d) U.S. Patent No. 5,279,543, issued 18 Jan 94, which was a file wrapper continuation application of (b), by Dr. Richard Guy, et al, and assigned to The Regents; and continuing applications thereof including divisions and substitutions but including continuation-in-part applications only to the extent that the claim was supported in the original disclosure; any patents issuing on said application or continuing applications including reissues and extensions; and any corresponding foreign applications or patents.
IPSCIO Record ID: 890
The Regents also grant to Licensee the right to issue exclusive or nonexclusive subLicenses to third parties.
U.S. Patent Application No. 10/131,384 entitled Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases, filed April 24, 2002, which was based on Provisional Application No. 60/286,842 filed 4/25/01 (UCLA Case Nos 1998-531-1,2) by Dr. Voskuhl, and assigned to The Regents.
U.S. Patent Application No. 10/984,364 entitled The Use of Estrial and Other Estranes, Estrogen and Estrogen Receptor Active Compositions in the Treatment of Psoriasis…, filed November 8, 2004, (UCLA Case No. 2004-101-3) by Drs. Rhonda R. Voskuhl, Gerald D. Weinstein and Jenny E. Murase and assigned to The Regents.
IPSCIO Record ID: 299293
Licensee is engaged in the discovery and development of innovative pharmaceuticals for the treatment of neurodegenerative diseases and other neurological and psychiatric disorders.
IPSCIO Record ID: 3951
Patent Application No. 61/030,316 entitled Screening Test for Gestational Diabetes Mellitus filed 02/21/2008 (UCLA Case No. 61/030,316.
IPSCIO Record ID: 203051
Certain invention (the Inventions), generally characterized as
1)
UCLA Case No. 1999-560: “NELL-1 Enhanced Bone Mineralizationâ€;
2)
UCLA Case No. 2004-331: “NELL1 Expression Systems and Neuroprotective Activity of NELL2â€;
3)
UCLA Case No. 2006-369: “Recombinant NELL-1 & 2 Protein Productionâ€;
4)
UCLA Case Number: 2009-271: “Recombinant NELL Protein Productionâ€;
5)
UCLA Case No. 2009-569: “NELL-1 Isoformâ€, and
6)
UCLA Case No. 2011-416: “Using NELL-1 to Inhibit Osteoclasts and to Prevent, Treat Osteoporosisâ€
Licensed Product means any article, composition, apparatus, substance, chemical, or any other material whose manufacture, use or sale would constitute an infringement of any Valid Claim within Regents Patent Rights, or any service, article, composition, apparatus, chemical, substance, or any other material made, used, or sold by or utilizing or practicing a Licensed Method. This definition of Licensed Product also includes a service either used by Licensee, an Affiliate, or Sublicensee or provided by Licensee, an Affiliate or Sublicensee to its customers when such service requires the use of Licensed Product or performance of Licensed Method.
Licensed Method means any process or method whose use or practice would constitute an infringement of any Valid Claim within Regents Patent Rights.
Regents Patent Rights:
1999-560-1
NELL-1 Enhanced Bone Mineralization
United States Of America
09/412,297
1999-560-2
NELL -1 Enhanced Bone Mineralization
United States Of America
11/392,294
1999-560-3
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …
United States Of America
11/594,510
1999-560-3
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …
European Patent Office
7871373.2
1999-560-3
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …
Canada
2668375
1999-560-4
NELL-1 Enhanced Bone Mineralization
United States Of America
11/713,366
1999-560-4
NELL-1 Enhanced Bone Mineralization
Canada
2679723
1999-560-6
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …
United States Of America
12/700,644
1999-560-8
NELL-1 Enhanced Bone Mineralization
United States Of America
13/011,736
2004-331-2
NELL Peptide Expression Systems And Bone Formation Activity Of Nell Peptide
United States Of America
10/544,553
2004-331-2
NELL Peptide Expression Systems and Bone Formation Activity of Nell Peptide
United Kingdom
4709500.5
2004-331-2
NELL Peptide Expression Systems and Bone Formation Activity of Nell Peptide
Spain
4709500.5
2004-331-2
NELL Peptide Expression Systems and Bone Formation Activity of NELL Peptide
Germany
4709500.5
2004-331-3
Expression System of NELL Peptide
United States Of America
11/601,529
2004-331-3
Expression System of NELL Peptide
European Patent Office
7868700.1
2004-331-7
Expression System of NELL Peptide
United States Of America
12/700,630
2006-369-2
Pharmaceutical Compositions for Treating or Preventing Bone Conditions
United States Of America
11/884,525
2006-369-3
Pharmaceutical Compositions for Treating or Preventing Bone Conditions
United States Of America
12/897,397
2009-271-2
Recombinant NELL Protein Production
United States Of America
13/121,394
2009-271-2
Recombinant NELL Protein Production
United Kingdom
9819839.3
2009-271-2
Recombinant NELL Protein Production
Spain
9819839.3
2009-271-2
Recombinant NELL Protein Production
Germany
9819839.3
2009-271-2
Recombinant NELL Protein Production
France
9819839.3
2009-569-2
Isoform NELL-1 Peptide
United States Of America
13/256,931
2009-569-2
Isoform NELL-1 Peptide
European Patent Office
10756811.5
2009-569-2
Isoform NELL-1 Peptide
Canada
2756168
2009-569-3
Isoform NELL-1 Peptide
United States Of America
15/265,680